Literature DB >> 21631263

Update on precursor and early lesions of hepatocellular carcinomas.

Young Nyun Park1.   

Abstract

CONTEXT: There is increasing evidence to support a multistep model of the process of human hepatocarcinogenesis. Precursor lesions are characterized by the appearance of dysplastic lesions in the form of microscopic dysplastic foci and macroscopic dysplastic nodules. There are 2 types of small hepatocellular carcinoma (HCC) (≤2 cm in diameter): (1) early HCC with an indistinct margin and (2) progressed HCC with a distinct margin. Pathologic diagnostic criteria for early HCC have recently been set up based on a consensus between Eastern and Western pathologists.
OBJECTIVE: To review the nomenclature, pathology, and biomarkers of precursor and early lesions of HCC. DATA SOURCES: Literature review and illustrations from case materials were used.
CONCLUSIONS: Dysplastic foci are composed of large and small cell changes. Small cell change is considered to be a more advanced precursor lesion than large cell change, and large cell change is a rather heterogeneous lesion that may represent both reactive change and true dysplasia. Dysplastic nodules can be categorized as low or high grade according to the degree of atypia. High-grade dysplastic nodules have been reported to show molecular changes similar to HCC and have a high risk of malignant transformation. Early HCC, which may correspond to microinvasive carcinomas of other organs, is a well-differentiated HCC, and differential diagnosis between early HCC and high-grade dysplastic nodule is difficult. Identification of stromal invasion and application of a panel of markers (glypican-3, heat shock protein 70, and glutamine synthetase) is helpful for diagnosis of early HCC. Detection of precursor lesions of HCC is important in recognizing patients with higher risk of developing HCC, and diagnosis of early HCC can improve patient survival by allowing for early and adequate treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21631263     DOI: 10.5858/2010-0524-RA.1

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  45 in total

1.  Consistency analysis of contrast-enhanced ultrasound and contrast-enhanced CT in diagnosis of small hepatocellular carcinoma.

Authors:  Jun-Jie Liu; Hong-Xue Li; Zhao-Bei Chen; Wei-Ping Yang; Sheng-Fa Zhao; Jie Chen; Tao Bai; Hang Li; Le-Qun Li
Journal:  Int J Clin Exp Med       Date:  2015-11-15

Review 2.  CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects.

Authors:  Jin-Young Choi; Jeong-Min Lee; Claude B Sirlin
Journal:  Radiology       Date:  2014-09       Impact factor: 11.105

3.  Differentiation of early hepatocellular carcinoma from benign hepatocellular nodules on gadoxetic acid-enhanced MRI.

Authors:  H Rhee; M-J Kim; M-S Park; K A Kim
Journal:  Br J Radiol       Date:  2012-05-02       Impact factor: 3.039

Review 4.  Histopathologic features of hepatocellular carcinoma.

Authors:  Elizabeth M Brunt
Journal:  Clin Liver Dis (Hoboken)       Date:  2013-01-23

Review 5.  Challenges in Diagnosis of Hepatocellular Carcinoma in Cirrhotic Liver: A Pathologist's Perspective.

Authors:  Dana Balitzer; Sanjay Kakar
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-05-01

Review 6.  Advances in computed tomography and magnetic resonance imaging of hepatocellular carcinoma.

Authors:  Tiffany Hennedige; Sudhakar K Venkatesh
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 7.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

Review 8.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

9.  Expression of K19 and K7 in dysplastic nodules and hepatocellular carcinoma.

Authors:  Jun Sang Bae; Ha Na Choi; Sang Jae Noh; Byung Hyun Park; Kyu Yun Jang; Cheol Keun Park; Woo Sung Moon
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

10.  Gadoxetic acid-enhanced MRI for hepatocellular carcinoma and hypointense nodule observed in the hepatobiliary phase.

Authors:  Elsa Iannicelli; Marco Di Pietropaolo; Massimo Marignani; Chiara Briani; Giulia Francesca Federici; Gianfranco Delle Fave; Vincenzo David
Journal:  Radiol Med       Date:  2013-12-03       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.